DIRS.INFO The most relevant business & tech news

☆ Analysis: As Putin sails to re-election, Russia’s leader has a succession problem
▼ + stars: | 2024-03-11 | by ( Nathan Hodge | ) edition.cnn.com time to read: +7 min

CNN —Russian President Vladimir Putin is widely expected to sail to re-election in a nationwide vote that begins on March 15, securing a fifth term in office and a full third decade as Russia’s paramount leader. As Kremlin chairman, Russian Prime Minister Mikhail Mishustin would become the country's leader temporarily if Putin were to die or be incarcerated while in office. In 2008, Putin reached the end of his second presidential term, and stepped aside for a handpicked placeholder, Dmitry Medvedev. Some Russian political observers speculate that the real competition to succeed Putin is not likely until the 2030s, when Putin reaches his sixth term. Even the former president Medvedev, who lost the number two slot in 2020 when he stepped down in a government shakeup, may still have aspirations.

Persons: Vladimir Putin, Alexey Navalny, Joseph Stalin, Putin, Dmitry Peskov, Putin “, Joe Biden, Putin’s, …, ”, Andreas Umland, “ Putin, ” Umland, Wagner, Yevgeny Prigozhin –, “ It’s, Umland, Mikhail Mishustin, Gleb Schelkunov, Dmitry Medvedev, Medvedev, Irina Buzhor, Leonid Brezhnev, Alexander Lukashenko, Xi Jinping, Nursultan Nazarbayev, Nazarbayev, President Kassym, Tokayev, Andrey Pertsev Organizations: CNN, Stockholm Centre, Eastern European Studies, Russian, Russian Federation, Soviet, Air Force One, United Russia, Russian Security Council, AP, Chinese Communist Party, country’s Security, Kremlin Locations: Soviet, Ukraine, Moscow, Russia, Russian, Belarusian, Kazakhstan

An upswing in the use of GLP-1 drugs has had a notable impact on the higher growth of pharmacy benefit costs under such health insurance plans, Mercer said. GLP-1 drugs, which work by suppressing hunger and making a person feel full longer, are typically priced around $1,000 per patient per month. While employers cover the use of GLP-1 drugs as a treatment for diabetes, the debate around providing coverage for them as an obesity treatment lingers. "It may take another couple of years for price increases stemming from higher healthcare sector wages and medical supply costs to be felt across all health plans." Despite rising health-plan costs, large employers have avoided shifting additional costs to employees through higher deductibles, co-pays, or out-of-pocket maximums in 2023.

Persons: Victoria Klesty, Mercer, Health Actuary, Sunit Patel, Eli Lilly's, Patel, Beth Umland, Khushi Mandowara, Leroy Leo, Pooja Desai Organizations: REUTERS, U.S . Food, Drug, Health, Reuters, Novo Nordisk's, Mercer, Thomson Locations: Oslo, Norway, August31, Victoria, United States, Bengaluru

Benefit consultants from Mercer, Aon (AON.N) and Willis Towers Watson (WTW.O) see employer healthcare costs jumping 5.4% to 8.5% in 2024 due to medical inflation, soaring demand for costly weight-loss drugs and wider availability of high-priced gene therapies. Benefit consultants help design insurance plans for medium and large employers. About two-thirds of U.S. workers receive benefits through such plans.Insurers UnitedHealth (UNH.N), Centene (CNC.N), Cigna (CI.N) and Elevance (ELV.N), which manage employer insurance plans, declined to comment for this story. Of its projected 8.5% increase in employer healthcare costs for next year, Aon anticipates 1 percentage point coming from weight-loss drugs alone. Gene therapy treatment of just one employee could significantly raise costs for a company, consultants said.

Persons: Srdjan, Willis Towers Watson, Mercer, Marsh McLennan, Beth Umland, Aon, Novo's Ozempic, Eli Lilly's, Janet Faircloth, Jodi Picoult's, Khushi Mandowara, Leroy Leo, Caroline Humer, Bill Berkrot Organizations: U.S, REUTERS, Reuters Graphics, Novo, Reuters, Employers, Thomson Locations: Ljubljana, Mercer, Aon, United States, Bengaluru

Search resuls for: "Umland"

3 mentions found